JMP Securities upgraded Sabra Health Care (SBRA) to Outperform from Market Perform with a $20 price target The firm expects “multiple tailwinds to result in outsized returns” for the stock.

I created Within This Party as a graduation project in 2022. The world was not much better back then, than it is today. Although perhaps on the surface, it was brighter. But there was darkness in ...

The first Saturday of the year sees Sandown as the focus for the latest antepost view and there's a strong possibility good ground is what we'll face. Two days of forecast rain is the hope for ...

On Dec. 5, Mizuho analyst Vikram Malhotra downgraded the rating for Sabra Health Care REIT from Outperform to Neutral and maintained the price target of $20. On Oct. 31, Sabra Health Care REIT ...

The Investment Committee give you their top stocks to watch for the second half. Game Changer review: Ram Charan's charm meets Shankar's old school direction in a Nayak, Sivaji: The Boss mashup ...

Fintel reports that on January 7, 2025, JMP Securities upgraded their outlook for Sabra Health Care REIT (NasdaqGS:SBRA) from Market Perform to Market Outperform. As of December 23, 2024 ...